Haemonetics Announces Major Update to Financial Reporting Segments
Key Highlights
- Haemonetics Corporation (NYSE: HAE) is restructuring its financial reporting segments to better align with how the company manages its business and allocates resources.
- The previous three reportable segments will be condensed into two: Apheresis (merging Plasma and Blood Center) and MedSurg (formerly Hospital segment).
- The new segment structure will be reflected in financial reporting starting with Q1 of fiscal year 2027 (commenced March 29, 2026).
- Supplemental revenue disclosures will continue, with Apheresis showing detail for Plasma and Other, and MedSurg including Blood Management Technologies and Interventional Technologies.
- A supplemental presentation with recast historical revenue for fiscal years 2024–2026 and a recast of FY27 revenue guidance is now available on the company’s Investor Relations website.
Details of the Segment Update
Haemonetics, a global leader in medical technology focused on improving patient outcomes, has announced a significant update to its external financial reporting structure. The company is moving from three reportable operating segments to two. The Plasma and Blood Center segments will be combined into a new, consolidated segment called Apheresis. The existing Hospital segment will be renamed MedSurg to better reflect its underlying business, technologies, and market focus.
This move is intended to provide stakeholders with a clearer understanding of the company’s operations by aligning external financial reporting with internal management and resource allocation practices. For investors, the new structure could provide more transparent insights into the company’s revenue drivers and operational focus going forward.
Implications for Investors & Shareholders
- Potential Share Price Impact: The restructuring of segments is a material event as it may affect how investors and analysts view the company’s performance, historical trends, and future guidance. Clarity and improved transparency in reporting can influence valuation and investor sentiment.
- Supplemental Disclosure: Haemonetics will continue to provide detailed revenue breakdowns within the new segments, allowing for comparison to previous years and better trend analysis. Notably, Apheresis will provide Plasma and Other detail, while MedSurg covers Blood Management and Interventional Technologies.
- Transition Timeline: The new reporting structure will be implemented with the first quarter results of FY27, which began on March 29, 2026. To assist stakeholders, the company has published a supplemental presentation with recast revenue data for fiscal years 2024, 2025, 2026, and an alignment of the previously issued FY27 revenue guidance.
- Guidance Not Reaffirmed: The company emphasizes that the supplemental presentation is not a reaffirmation or update of prior fiscal year 2027 guidance. Any updates or changes to guidance will be discussed in the upcoming Q1 FY27 earnings call.
- Access to Information: The recast supplemental presentation is available on Haemonetics’ Investor Relations website, enabling investors to analyze the changes in detail.
Company Overview
Haemonetics is a leading medical technology company dedicated to improving the quality, effectiveness, and efficiency of healthcare. The firm delivers innovative solutions across hospital technologies, plasma collection, and blood component collection, serving critical medical needs worldwide.
Forward-Looking Statements & Risks
Investors should note that this press release includes forward-looking statements, which involve risks and uncertainties. Such statements concern the implementation of the new segment reporting structure, future financial results, and the underlying assumptions. Actual results may differ materially due to various factors, including but not limited to:
- Market demand for Haemonetics’ products
- Success in developing and marketing new products
- Competitive pressures and pricing
- Product quality issues or cybersecurity disruptions
- Regulatory uncertainties and potential delays in approvals
- Global economic and political changes, including inflation and tariff policies
- Impacts from acquisitions, divestitures, manufacturing, and supply chain disruptions
- Effectiveness of cost-saving initiatives and the share repurchase program
- Litigation, intellectual property protection, and other risks detailed in SEC filings
Haemonetics does not undertake any obligation to update forward-looking statements, except as required by law.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review all available materials and consult independent financial advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties and actual results may differ materially.
